BioSpace News Archive

Elizabeth Holmes blames the allegations of investor fraud perpetrated by her blood-testing company Theranos at the feet of her former business partner Ramesh “Sunny” Balwani.

Pfizer veteran Phil Dormitzer will assume the role of Global Head of Vaccines beginning Friday.

Secura Bio, Inc. (Secura Bio) - (www.securabio.com), announced today that, based on discussions with the U.S. Food and Drug Administration (FDA), Secura Bio has submitted to FDA for the withdrawal of the approval of NDA 205353 for FARYDAK® (panobinostat) oral capsules.

Amedisys, Inc. (NASDAQ: AMED), a leading provider of home health, hospice, personal care and high acuity care services, today announced that Paul B. Kusserow, Chairman and Chief Executive Officer, Chris Gerard, President and Chief Operating Officer and Scott Ginn, Executive Vice President and Chief Financial Officer will present at the Bank of America Securities 2021 Virtual Healthcare Conference.

The installation of the NGB (Next-Generation Bioprinting) robotic bioprinting platform developed by Poietis in the Advanced Therapy Medicinal Product manufacturing area of the Hôpital de la Conception represents a world premiere and opens up very promising perspectives in regenerative medicine.

Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that the Brazilian Health Regulatory Agency (Agencia Nacional de Vigilancia Sanitaria or ‘Anvisa’) has granted an exceptional authorisation for Illuccix® (TLX591-CDx) the Company’s lead prostate cancer imaging product.

Regulus Therapeutics Inc., a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, announced the closing of its previously announced private placement of equity.

Molecular Templates, Inc., a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies, provided a corporate update and outlined expected 2022 milestones.

CTI BioPharma Corp. (Nasdaq: CTIC) today announced the U.S. Food and Drug Administration (FDA) has extended the review period for the New Drug Application (NDA) for pacritinib for the treatment of adult patients with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis (MF) with a baseline platelet count of <50 × 109/L.

Sarepta Therapeutics, Inc., the leader in precision genetic medicine for rare diseases, granted equity awards on November 30, 2021 that were previously approved by the Compensation Committee of its Board of Directors under Sarepta’s 2014 Employment Commencement Incentive Plan, as a material inducement to employment to 35 individuals hired by Sarepta in November 2021.